Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome - PubMed (original) (raw)
Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome
B M Lodde et al. Ann Rheum Dis. 2006 Feb.
Abstract
Background: Sjögren's syndrome (SS), an autoimmune exocrinopathy mainly affecting lachrymal and salivary glands, results in ocular and oral dryness (keratoconjunctivitis sicca and xerostomia). The aetiology and pathogenesis are largely unknown; currently, only palliative treatment is available.
Objective: To determine whether gene transfer of vasoactive intestinal peptide (VIP), based on its immunomodulatory properties, might be useful in the management of SS.
Methods: A recombinant serotype 2 adeno-associated virus encoding the human VIP transgene (rAAV2hVIP) was constructed and its efficacy tested in the female non-obese diabetic (NOD) mouse model for SS after retrograde instillation in submandibular glands (SMGs). 10(10) particles/gland of rAAV2hVIP or rAAV2LacZ (encoding beta-galactosidase; control vector) were administered at 8 weeks of age (before sialadenitis onset). Salivary flow rates were determined before vector delivery and at time of death (16 weeks). After death, saliva, serum, and SMGs were harvested. Salivary output, inflammatory infiltrates (focus scores), VIP protein expression, cytokine profile, and serum anti-VIP antibodies were analysed.
Results: rAAV2hVIP significantly improved the salivary flow, increased SMG and serum expression of VIP, and reduced SMG cytokines interleukin (IL) 2, IL10, IL12 (p70), and tumour necrosis factor alpha, and serum RANTES, compared with the control vector. No difference in focus scores or apoptotic rates was found; neutralising antibodies were not detected.
Conclusions: Local delivery of rAAV2hVIP can have disease modifying and immunosuppressive effects in SMGs of the NOD mouse model of SS. The new strategy of employing VIP prophylactically may be useful for both understanding and managing the salivary component of SS.
Figures
Similar articles
- Vasoactive intestinal peptide/vasoactive intestinal peptide receptor relative expression in salivary glands as one endogenous modulator of acinar cell apoptosis in a murine model of Sjögren's syndrome.
Hauk V, Calafat M, Larocca L, Fraccaroli L, Grasso E, Ramhorst R, Leirós CP. Hauk V, et al. Clin Exp Immunol. 2011 Dec;166(3):309-16. doi: 10.1111/j.1365-2249.2011.04478.x. Clin Exp Immunol. 2011. PMID: 22059987 Free PMC article. - NOD mouse model for Sjögren's syndrome: lack of longitudinal stability.
Lodde BM, Mineshiba F, Kok MR, Wang J, Zheng C, Schmidt M, Cotrim AP, Kriete M, Tak PP, Baum BJ. Lodde BM, et al. Oral Dis. 2006 Nov;12(6):566-72. doi: 10.1111/j.1601-0825.2006.01241.x. Oral Dis. 2006. PMID: 17054769 - Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjögren's syndrome.
Kok MR, Yamano S, Lodde BM, Wang J, Couwenhoven RI, Yakar S, Voutetakis A, Leroith D, Schmidt M, Afione S, Pillemer SR, Tsutsui MT, Tak PP, Chiorini JA, Baum BJ. Kok MR, et al. Hum Gene Ther. 2003 Nov 20;14(17):1605-18. doi: 10.1089/104303403322542257. Hum Gene Ther. 2003. PMID: 14633403 - Use of localised gene transfer to develop new treatment strategies for the salivary component of Sjögren's syndrome.
Kok MR, Baum BJ, Tak PP, Pillemer SR. Kok MR, et al. Ann Rheum Dis. 2003 Nov;62(11):1038-46. doi: 10.1136/ard.62.11.1038. Ann Rheum Dis. 2003. PMID: 14583564 Free PMC article. Review. - Sjögren's syndrome. Controversies and progress.
Fox RI. Fox RI. Clin Lab Med. 1997 Sep;17(3):431-44. Clin Lab Med. 1997. PMID: 9316767 Review.
Cited by
- Transient TWEAK overexpression leads to a general salivary epithelial cell proliferation.
Sugito T, Mineshiba F, Zheng C, Cotrim AP, Goldsmith CM, Baum BJ. Sugito T, et al. Oral Dis. 2009 Jan;15(1):76-81. doi: 10.1111/j.1601-0825.2008.01474.x. Epub 2008 Sep 29. Oral Dis. 2009. PMID: 18992019 Free PMC article. - Neutralizing antibodies against adeno-associated viruses in Sjögren's patients: implications for gene therapy.
Corden A, Handelman B, Yin H, Cotrim A, Alevizos I, Chiorini JA. Corden A, et al. Gene Ther. 2017 Apr;24(4):241-244. doi: 10.1038/gt.2017.1. Epub 2017 Feb 2. Gene Ther. 2017. PMID: 28150697 Free PMC article. - Vasoactive intestinal peptide/vasoactive intestinal peptide receptor relative expression in salivary glands as one endogenous modulator of acinar cell apoptosis in a murine model of Sjögren's syndrome.
Hauk V, Calafat M, Larocca L, Fraccaroli L, Grasso E, Ramhorst R, Leirós CP. Hauk V, et al. Clin Exp Immunol. 2011 Dec;166(3):309-16. doi: 10.1111/j.1365-2249.2011.04478.x. Clin Exp Immunol. 2011. PMID: 22059987 Free PMC article. - Lentiviral gene therapy vectors encoding VIP suppressed diabetes-related inflammation and augmented pancreatic beta-cell proliferation.
Erendor F, Sahin EO, Sanlioglu AD, Balci MK, Griffith TS, Sanlioglu S. Erendor F, et al. Gene Ther. 2021 Apr;28(3-4):130-141. doi: 10.1038/s41434-020-0183-3. Epub 2020 Jul 30. Gene Ther. 2021. PMID: 32733091 - A Clinical Approach for the Use of VIP Axis in Inflammatory and Autoimmune Diseases.
Martínez C, Juarranz Y, Gutiérrez-Cañas I, Carrión M, Pérez-García S, Villanueva-Romero R, Castro D, Lamana A, Mellado M, González-Álvaro I, Gomariz RP. Martínez C, et al. Int J Mol Sci. 2019 Dec 20;21(1):65. doi: 10.3390/ijms21010065. Int J Mol Sci. 2019. PMID: 31861827 Free PMC article. Review.
References
- Jonsson R, Hagan H‐J, Gordon T. Sjögren's syndrome. In: Koopman WJ, ed. Arthritis and allied conditions ‐ a textbook of rheumatology. 14th ed. Philadelphia: Lippincott Williams & Wilkins, February20011736–1759.
- Cha S, Peck A B, Humphreys‐Beher M G. Progress in understanding autoimmune exocrinopathy using the non‐obese diabetic mouse: an update. Crit Rev Oral Biol Med 2002135–16. - PubMed
- Borchers A T, Naguwa S M, Keen C L, Gershwin M E. Immunopathogenesis of Sjögren's syndrome. Clin Rev Allergy Immunol 20032589–104. - PubMed
- Said S I. Vasoactive intestinal peptide. J Endocrinol Invest 19869191–200. - PubMed
- Gozes I, Furman S. VIP and drug design. Curr Pharm Des 20039483–494. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical